Serostim $704 Mil. Settlement Is Largest For Off-Label Marketing Case
Executive Summary
Serono's $704 mil. settlement over Serostim promotional practices marks the largest penalty ever paid by a pharmaceutical manufacturer to resolve civil and criminal investigations into off-label marketing
You may also be interested in...
When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA
Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.
When Is On-Label Speech Off-Label Promotion? Par Links The Two In Suit Against FDA
Par Pharmaceutical Inc.’s First Amendment suit against FDA offers a new approach to battling government allegations of off-label marketing.
Merck Serono Settlement On Rebif Kickbacks Expands, Extends Existing Integrity Agreement With OIG
The company agrees to pay $44.3 million under a deal with the Department of Justice and tack three years onto a corporate integrity agreement in effect since 2005.